\
&
Contact us
\
&
Contact us
Starts in 2 months from now
LocationOnline
ProgrammesThis webinar is organised by the European Innovation Council and SMEs Executive Agency through the European IP Helpdesk.
The webinar will cover the background and purpose of the EU AI Act, key provisions and requirements, compliance and implementation, ethical and social considerations, case studies, and possible future developments.
Target group: researchers, innovators, SMEs, companies, and organisations working with AI or interested in how EU rules may affect AI development and use.
Please find more information and registration here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
